Aimmune Therapeutics Inc AIMT:NASDAQ

Last Price$16.02NASDAQ Previous Close - Last Trade as of 4:00PM ET 4/09/20

Today's Change+0.16(1.01%)
Bid (Size)$15.60 (5)
Ask (Size)$17.00 (2)
Day Low / High$15.61 - 16.84
Volume1.5 M
 

View Biotechnology IndustryPeer Comparison as of 04/09/2020

 

Aimmune Therapeutics Inc ( NASDAQ )

Price: $16.02
Change: +0.16 (1.01%)
Volume: 1.5 M
4:00PM ET 4/09/2020
 
 

Enanta Pharmaceuticals Inc ( NASDAQ )

Price: $53.04
Change: +0.87 (1.67%)
Volume: 163.3 K
3:59PM ET 4/09/2020
 
 

Twist Bioscience Corp ( NASDAQ )

Price: $26.90
Change: -0.53 (1.93%)
Volume: 320.9 K
3:59PM ET 4/09/2020
 
 

NGM Biopharmaceuticals Inc ( NASDAQ )

Price: $15.27
Change: 0.00 (0.00%)
Volume: 329.7 K
3:59PM ET 4/09/2020
 
 

Myriad Genetics Inc ( NASDAQ )

Price: $15.24
Change: -0.01 (0.07%)
Volume: 834.7 K
3:59PM ET 4/09/2020
 

Read more news Recent News

Insider Trends: Insider Buying Extended with Purchase of AIMSI Technologies Stock
5:05PM ET 3/19/2020 MT Newswires

Patrick G Enright, Director, made a purchase of 125,000 shares in AIMSI Technologies (AIMT) on Mar 17, 2020, for $1,420,045. After the Form 4 filing with...

Insider Trends: Insider Purchase Adds to Aimmune Therapeutics Positive Trend
5:05PM ET 3/19/2020 MT Newswires

Patrick G Enright, Director, on Mar 17, 2020, executed a purchase for 125,000 shares in Aimmune Therapeutics (AIMT) for $1,420,045. Enright has control...

--Analyst Actions: JMP Securities Downgrades Aimmune Therapeutics to Market Perform From Market Outperform
9:52AM ET 3/18/2020 MT Newswires

Price: 11.09, Change: -0.42, Percent Change: -3.65 ...

Aimmune Therapeutics Says First Patients in US Being Treated With Peanut Allergy Drug Palforzia
11:18AM ET 3/16/2020 MT Newswires

Aimmune Therapeutics (AIMT) announced Monday the first US patients being treated with Palforzia for peanut allergy. The drug, which was approved by the US...

Company Profile

Business DescriptionAimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The firm product include Palforzia, which is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis that may occur with accidental exposure to peanut. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA. View company web site for more details
Address8000 Marina Boulevard
Brisbane, California 94005-1884
Phone+1.650.614.5220
Number of Employees215
Recent SEC Filing04/09/2020DEFA14A
President, Chief Executive Officer & DirectorJayson Donald Alexander Dallas
Chief Financial OfficerEric Hands Claude Bjerkholt
Chief Medical OfficerDaniel C. Adelman
Senior VP-Corporate Development & StrategyMary M. Rozenman

Company Highlights

Price Open$16.32
Previous Close$15.86
52 Week Range$10.09 - 37.00
Market Capitalization$1.0 B
Shares Outstanding62.7 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement05/13/2020

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$3.97
Beta vs. S&P 500N/A
Revenue$0.00
Net Profit MarginN/A
Return on Equity-138.44%

Analyst Ratings as of 03/17/2020

Buy
5
Overweight
1
Hold
5
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset